Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.30 -4.7%	$0.34	$0.27 ▼ $1.23	$60.41M	1.03	119,357 shs	58,328 shs
CTMX CytomX Therapeutics	$2.75 -8.0%	$1.56	$0.40 ▼ $3.10	$221.71M	2.11	2.15 million shs	1.97 million shs
SLRN Acelyrin	$2.27	$2.28	$1.85 ▼ $7.25	$229.17M	1.07	1.26 million shs	N/A
YMAB Y-mAbs Therapeutics	$4.71 +1.7%	$4.44	$3.55 ▼ $16.11	$213.29M	0.52	304,554 shs	472,812 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	0.00%	-7.66%	-14.64%	-9.08%	-69.69%
CTMX CytomX Therapeutics	0.00%	+4.17%	+37.50%	+323.34%	+84.56%
SLRN Acelyrin	0.00%	0.00%	+4.61%	-17.45%	-50.76%
YMAB Y-mAbs Therapeutics	0.00%	-10.63%	+22.02%	+0.86%	-60.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	1.1699 of 5 stars	0.0	3.0	0.0	0.0	2.1	1.7	1.3
CTMX CytomX Therapeutics	4.2774 of 5 stars	3.5	1.0	0.0	4.7	2.6	2.5	1.3
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	3.5485 of 5 stars	4.4	2.0	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	4.00	Strong Buy	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	93.94% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	231.21% Upside

Current Analyst Ratings Breakdown

Latest AAWH, SLRN, CTMX, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.12	$0.04 per share	6.64	$0.69 per share	0.43
CTMX CytomX Therapeutics	$147.56M	1.50	N/A	N/A	($0.71) per share	-3.87
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
YMAB Y-mAbs Therapeutics	$88.66M	2.41	N/A	N/A	$2.32 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.40	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
CTMX CytomX Therapeutics	-$570K	$0.48	16.18	N/A	N/A	10.96%	-41.47%	8.11%	8/6/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.64	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	8/11/2025 (Estimated)

Latest AAWH, SLRN, CTMX, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
CTMX CytomX Therapeutics	N/A	1.04	1.04
SLRN Acelyrin	N/A	7.15	7.15
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.32%
CTMX CytomX Therapeutics	67.77%
SLRN Acelyrin	87.31%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.38%
CTMX CytomX Therapeutics	6.60%
SLRN Acelyrin	13.60%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.44 million	166.44 million	Not Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

AAWH, SLRN, CTMX, and YMAB Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Consensus PT from Brokerages

June 12 at 3:00 AM | americanbankingnews.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Wesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on YMAB FY2026 Earnings

June 10, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from Analysts

June 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE

June 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer

May 30, 2025 | marketbeat.com

Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Infinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 28, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.com

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

HC Wainwright Brokers Decrease Earnings Estimates for YMAB

May 23, 2025 | marketbeat.com

FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 20, 2025 | marketbeat.com

Wedbush Cuts Earnings Estimates for Y-mAbs Therapeutics

May 17, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAWH, SLRN, CTMX, and YMAB Company Descriptions

Ascend Wellness OTC:AAWH

$0.30 -0.01 (-4.68%)

As of 06/13/2025 03:48 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

CytomX Therapeutics NASDAQ:CTMX

$2.75 -0.24 (-8.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.09 (+3.31%)

As of 06/13/2025 07:57 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.71 +0.08 (+1.73%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.70 -0.01 (-0.21%)

As of 06/13/2025 06:38 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time